Literature DB >> 26881519

Cyclooxygenase-2 expression is associated with elevated aspartate aminotransferase level in hepatocellular carcinoma.

Eman A Bayomi, Ahmed B Barakat, Maha A El-Bassuoni, Randa M Talaat, Mervat M El-Deftar, Sabrin A Abdel Wahab, Ayman M Metwally1.   

Abstract

BACKGROUND: Cyclooxygenase-2 (COX-2), the inducible rate-limiting enzyme of prostaglandins biosynthesis, is involved in the pathogenesis of many chronic inflammation-related human malignancies including hepatocellular carcinoma (HCC). However, its clinical significance in HCC remains obscure. The aim of our study was to evaluate COX-2 expression in HCC and correlate its expression to both clinicopathological parameters and patients survival.
MATERIALS AND METHODS: The present study was conducted on 17 HCC and 21 adjacent nontumor liver tissues obtained from 22 HCC patients underwent hepatectomy. Eight normal liver tissues taken from normal donors and HepG2 cells were used as controls. Total RNA was extracted and COX-2 mRNA was detected by reverse transcription polymerase chain reaction and correlated to the clinicopathological criteria and to patient's survival.
RESULTS: COX-2 mRNA was detected in 58.8% of the HCC tissues and in 28.6% of the adjacent nontumor liver tissues. COX-2 expression was significantly associated with elevated levels of serum aspartate aminotransferase (AST) with high specificity for disease detection. There was no significance between COX-2 expression and any of the histopathological criteria.
CONCLUSIONS: COX-2 expression may be involved in HCC carcinogenesis with high specificity for disease detection. COX-2 expression is significantly associated with elevated AST levels indicating a mechanism that may correlate both markers. However COX-2 expression seems to be an independent factor with no correlation to any of the histopathological data or patient's survival.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26881519     DOI: 10.4103/0973-1482.147692

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  6 in total

Review 1.  Cysteine Aminotransferase (CAT): A Pivotal Sponsor in Metabolic Remodeling and an Ally of 3-Mercaptopyruvate Sulfurtransferase (MST) in Cancer.

Authors:  Ana Hipólito; Sofia C Nunes; João B Vicente; Jacinta Serpa
Journal:  Molecules       Date:  2020-09-01       Impact factor: 4.411

2.  miR-26b Mimic Inhibits Glioma Proliferation In Vitro and In Vivo Suppressing COX-2 Expression.

Authors:  Zheng-Gang Chen; Chuan-Yi Zheng; Wang-Qing Cai; Da-Wei Li; Fu-Yue Ye; Jian Zhou; Ran Wu; Kun Yang
Journal:  Oncol Res       Date:  2017-08-11       Impact factor: 5.574

3.  Metabolomics and eicosanoid analysis identified serum biomarkers for distinguishing hepatocellular carcinoma from hepatitis B virus-related cirrhosis.

Authors:  Zhi-Gang Gong; Weijie Zhao; Jianbing Zhang; Xi Wu; Jing Hu; Guo-Chang Yin; Yong-Jiang Xu
Journal:  Oncotarget       Date:  2017-07-10

4.  Impact of cyclooxygenase-2 over-expression on the prognosis of colorectal cancer patients. An experience from Western Saudi Arabia.

Authors:  Abdulkader M Albasri; Mohammed A Elkablawy; Akbar S Hussainy; Hala M Yousif; Ahmed S Alhujaily
Journal:  Saudi Med J       Date:  2018-08       Impact factor: 1.484

5.  The Ethanol Supernatant Extracts of Liushenwan Could Alleviate Nanodiethylnitrosamine-Induced Liver Cancer in Mice.

Authors:  Xi-Zhen Chen; Wei Kevin Zhang; He-Bin Tang; Xiao-Jun Li; Gui-Hua Tian; Hong-Cai Shang; Yu-Sang Li
Journal:  Can J Gastroenterol Hepatol       Date:  2018-09-26

6.  The high expression of TNF-α and NF-κB in tumor microenvironment predicts good prognosis of patients with BCLC-0-B hepatocellular carcinoma.

Authors:  Haoran Li; Yanhua Wang; Mao Zhang; Jie Hu; Zixiang Li; Bing Han
Journal:  Transl Cancer Res       Date:  2019-04       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.